{"id":53472,"date":"2023-01-31T17:03:14","date_gmt":"2023-01-31T16:03:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/"},"modified":"2023-01-31T17:03:14","modified_gmt":"2023-01-31T16:03:14","slug":"after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/","title":{"rendered":"After Record Growth in 2022, Etiometry Paves Way for 2023 Expansion"},"content":{"rendered":"
\n

\n150+ million hours of data signals, regulatory approvals key to Etiometry\u2019s upward trajectory\n<\/p>\n

BOSTON–(BUSINESS WIRE)–#clinicaldecisionsupport<\/a>—Etiometry<\/a>, the leader in clinical decision-support software for critical care, today provided a glimpse into its 2023 priorities as well as highlights from 2022, which marked a landmark year of growth for the company \u2013 including its database volume, which now exceeds 150 million hours of deidentified data signals. These patient-generated data are key to scaling Etiometry\u2019s technology to serve additional populations and inform the company\u2019s risk algorithms, which bolster the platform\u2019s use as a safety net for clinicians caring for critically ill patients.\n<\/p>\n

<\/a><\/p>\n

\nOn the heels of record growth in 2021, Etiometry harnessed the momentum moving into 2022, more than doubling sales over 2021, and also initiated its first adult hospital installations.\n<\/p>\n

\nOn the regulatory front, Etiometry announced this month its eighth FDA clearance<\/a>; the IDO2 IndexTM<\/sup> is now cleared for adult use. In 2022, the company doubled its FDA-cleared risk analytics portfolio to four indices, adding the HLA Index\u2122 for hyperlactatemia, and ACD Index\u2122 for acidemia, further strengthening its capability to track the fundamental pathways through which patients deteriorate under intensive care. In other markets, the company received CE Marking<\/a> and Health Canada<\/a> authorization for all four risk algorithms in pediatrics and the additional approval of the ID02 algorithm in adults in each geography.\n<\/p>\n

\n\u201cOur regulatory success uniquely positions Etiometry for further developments in 2023 that will result in enhanced offerings benefiting patients and the care teams treating them,\u201d said Shane Cooke, CEO of Etiometry. \u201cWe\u2019ve also seen a substantial uptick in clinicians using the platform\u2019s data for research.\u201d\n<\/p>\n

\nSix peer-reviewed articles were published about the Etiometry platform in 2022, bringing the total to 12 journals and adding to the more than 120 ongoing research projects, which include 15 multi-center studies.\n<\/p>\n

\nAs the body of research highlighting the clinical efficacy of the Etiometry platform continues to grow, so does the attention from industry stakeholders. Following its 2021 strategic partnership with Terumo, last year, Etiometry formed its second partnership<\/a> with Radiometer, a medical device company specializing in acute care testing solutions to enhance neonatal intensive care outcomes.\n<\/p>\n

\nIn October, clinicians from some of the nation\u2019s top-ranked hospitals participated in Etiometry\u2019s Guiding Patient Safety Summit<\/a> to discuss how the platform can impact patient care and improve daily workflows. Capping off the year, Frost & Sullivan<\/a> presented Etiometry with its Enabling Technology Leadership Award for critical care decision making.\n<\/p>\n

\nIn 2023, Etiometry aims to maintain its regulatory tempo, add new customers across pediatric and adult hospital systems, and continue to expand its utilization footprint by installing the platform in more intensive care units, operating rooms, and emergency departments \u2013 a number that has already grown by a factor of four over the past two years. Etiometry also plans to add to its talent pool \u2013 which currently includes clinicians to inform product developments, as well as data science experts to expand the reach of the company\u2019s AI-based platform.\n<\/p>\n

\n\u201cAside from the strides we\u2019re making in enhancing our platform\u2019s capabilities, it\u2019s exciting to pique the interest of more and more hospital leaders. The driver is always about enhancing patient care while reducing length of stay and readmissions,\u201d said Cooke, \u201cBut, I would add that by decreasing the cognitive burden of care teams, Etiometry provides a concrete way to alleviate clinician burnout, which we all know, is a persisting problem. There really hasn\u2019t been a better time for our solution.\u201d\n<\/p>\n

\nAbout Etiometry<\/b>\n<\/p>\n

\nFounded in 2010, Etiometry is the leader in clinical decision-support software designed to help clinicians in the intensive care setting make data-based decisions regarding their patients\u2019 care and treatment. The company\u2019s technologies provide valuable clinical insight and analysis to support early recognition of subtle changes in patients\u2019 conditions to avoid complications and speed recovery. Etiometry has eight FDA clearances and four Health Canada approvals and CE markings. With roots in pediatric ICUs, Etiometry\u2019s software is utilized by some of the world\u2019s top academic medical centers, 20 of the Best Children\u2019s Hospitals, ranked by U.S. News & World Report<\/i>, 4 out of 5 of the highest ranked children\u2019s hospitals in Newsweek\u2019s<\/i> Top Specialty Hospitals in the World and a growing number of top adult hospitals. Etiometry is committed to improving patient outcomes, increasing clinical efficiency, and lowering the cost of care through the more effective use of data.\n<\/p>\n

\nThe Etiometry Platform<\/b> is an end-to-end data management software solution for the collection, analysis, visualization, and archiving of ICU clinical data. It is designed to facilitate the use of all available data to support the anticipation and management of the dynamic condition of patients requiring intensive care. To learn more, visit www.etiometry.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Andrew Young
\n
615-603-1574
\n
Andrew@hencove.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

150+ million hours of data signals, regulatory approvals key to Etiometry\u2019s upward trajectory BOSTON–(BUSINESS WIRE)–#clinicaldecisionsupport—Etiometry, the leader in clinical decision-support software for critical care, today provided a glimpse into its 2023 priorities as well as highlights from 2022, which marked a landmark year of growth for the company \u2013 including its database volume, which now … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53472","6":"format-standard","7":"category-industry"},"yoast_head":"\nAfter Record Growth in 2022, Etiometry Paves Way for 2023 Expansion - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"After Record Growth in 2022, Etiometry Paves Way for 2023 Expansion - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"150+ million hours of data signals, regulatory approvals key to Etiometry\u2019s upward trajectory BOSTON–(BUSINESS WIRE)–#clinicaldecisionsupport—Etiometry, the leader in clinical decision-support software for critical care, today provided a glimpse into its 2023 priorities as well as highlights from 2022, which marked a landmark year of growth for the company \u2013 including its database volume, which now ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-31T16:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230131005783\/en\/1700933\/21\/etiometry_logo_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"After Record Growth in 2022, Etiometry Paves Way for 2023 Expansion\",\"datePublished\":\"2023-01-31T16:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\\\/\"},\"wordCount\":793,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005783\\\/en\\\/1700933\\\/21\\\/etiometry_logo_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\\\/\",\"name\":\"After Record Growth in 2022, Etiometry Paves Way for 2023 Expansion - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005783\\\/en\\\/1700933\\\/21\\\/etiometry_logo_RGB.jpg\",\"datePublished\":\"2023-01-31T16:03:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005783\\\/en\\\/1700933\\\/21\\\/etiometry_logo_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005783\\\/en\\\/1700933\\\/21\\\/etiometry_logo_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"After Record Growth in 2022, Etiometry Paves Way for 2023 Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"After Record Growth in 2022, Etiometry Paves Way for 2023 Expansion - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/","og_locale":"en_US","og_type":"article","og_title":"After Record Growth in 2022, Etiometry Paves Way for 2023 Expansion - Pharma Trend","og_description":"150+ million hours of data signals, regulatory approvals key to Etiometry\u2019s upward trajectory BOSTON–(BUSINESS WIRE)–#clinicaldecisionsupport—Etiometry, the leader in clinical decision-support software for critical care, today provided a glimpse into its 2023 priorities as well as highlights from 2022, which marked a landmark year of growth for the company \u2013 including its database volume, which now ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-31T16:03:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230131005783\/en\/1700933\/21\/etiometry_logo_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"After Record Growth in 2022, Etiometry Paves Way for 2023 Expansion","datePublished":"2023-01-31T16:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/"},"wordCount":793,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230131005783\/en\/1700933\/21\/etiometry_logo_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/","url":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/","name":"After Record Growth in 2022, Etiometry Paves Way for 2023 Expansion - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230131005783\/en\/1700933\/21\/etiometry_logo_RGB.jpg","datePublished":"2023-01-31T16:03:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230131005783\/en\/1700933\/21\/etiometry_logo_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230131005783\/en\/1700933\/21\/etiometry_logo_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/after-record-growth-in-2022-etiometry-paves-way-for-2023-expansion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"After Record Growth in 2022, Etiometry Paves Way for 2023 Expansion"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53472"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53472\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}